The American Oncology Network was ranked number 107 on the 2022 Inc. 5000 Annual List.
Fort Myers, Fla., August 18, 2022 – American Oncology Network, LLC (AON) was ranked number 107 on the annual Inc. 5000 list, the most prestigious ranking of the fastest-growing private companies in America. AON also received the number 8 position in the health services category.
Among the top 500, the average median 3-year revenue growth rate soared to 2144%. Together, those companies added more than 68,394 jobs over the past 3 years.
“We are honored to be recognized as one of the nation’s fastest-growing private companies by Inc.,” said AON chief executive officer Todd Schonherz. “At AON, we believe the key to accessible and equitable health care lies in the strength of community healthcare practices, which is why we strive to support community oncology practices, large and small. This recognition is a reminder that we are taking the right steps in forwarding our mission by providing support and resources for hometown oncology practices and breaking down barriers to cancer care.”
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
Bridging Care Gaps With a Systemwide Value-Based Care Strategy
March 29th 2025Mapping care management needs by defining patient populations and then stratifying them according to risk and their needs can help to spur the transformation of a siloed health care system into an integrated system that is able to better provide holistic, value-based care despite the many transitions that continue among hospital, primary, specialty, and community care environments.
Read More
Understanding Primary and Secondary Nonadherence to Chronic Oral Medication
March 28th 2025Medication nonadherence to oral anticoagulants and oral anti–prostate cancer medication has been scrutinized through new research conducted among patients and health care providers and presented by the American Medical Group Association at its 2025 annual meeting, held March 26-29 in Grapevine, Texas.
Read More